British pharmaceutical company GlaxoSmithKline reported on Wednesday its earnings in the fourth quarter of fiscal 2019, with revenue standing at £8.90 billion, missing projections by around £100 million but rising 8.5% year-over-year.
However, the company surprised on the rest of the metrics, including earnings per share, reporting 24.8 pence versus market estimates of 24.5 pence. Sales of Shingrix, one of GSK's most profitable products, amounted to £1.8 billion, topping market expectations.
For the whole year, the Brentford-based company posted revenue of £33.75 billion, up 9% on an annual scale. Full-year EPS amounted to 123.9 pence, a 3% rise year-on-year.
GSK's share traded 1.54% in the green at 1:09 pm ET.